JP2020523022A - 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 - Google Patents

免疫療法に反応する肝細胞癌のクラスの検出および治療方法 Download PDF

Info

Publication number
JP2020523022A
JP2020523022A JP2019568654A JP2019568654A JP2020523022A JP 2020523022 A JP2020523022 A JP 2020523022A JP 2019568654 A JP2019568654 A JP 2019568654A JP 2019568654 A JP2019568654 A JP 2019568654A JP 2020523022 A JP2020523022 A JP 2020523022A
Authority
JP
Japan
Prior art keywords
gene
immunotherapy
subject
genes
expression profile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019568654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523022A5 (enExample
Inventor
シア，ダニエラ
アイ ベイヤー，ジョセップ，マリア リョベート
アイ ベイヤー，ジョセップ，マリア リョベート
ビリャヌエバ−ロドリゲス，アウグスト
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2020523022A publication Critical patent/JP2020523022A/ja
Publication of JP2020523022A5 publication Critical patent/JP2020523022A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019568654A 2017-06-14 2018-06-14 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 Pending JP2020523022A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519711P 2017-06-14 2017-06-14
US62/519,711 2017-06-14
US201862629231P 2018-02-12 2018-02-12
US62/629,231 2018-02-12
PCT/US2018/037579 WO2018232142A1 (en) 2017-06-14 2018-06-14 Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy

Publications (2)

Publication Number Publication Date
JP2020523022A true JP2020523022A (ja) 2020-08-06
JP2020523022A5 JP2020523022A5 (enExample) 2021-07-26

Family

ID=64660235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019568654A Pending JP2020523022A (ja) 2017-06-14 2018-06-14 免疫療法に反応する肝細胞癌のクラスの検出および治療方法

Country Status (5)

Country Link
US (1) US11473150B2 (enExample)
EP (1) EP3638695A4 (enExample)
JP (1) JP2020523022A (enExample)
CN (1) CN111164103A (enExample)
WO (1) WO2018232142A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112564A1 (en) * 2019-02-14 2022-04-14 Merck Sharp & Dohme Corp. Gene expression based biomarker of tumor response to pd-1 antagonists
IL291748A (en) * 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
EP3868897A1 (en) * 2020-02-20 2021-08-25 Worldwide Innovative Network Method for improving the treatment with immune checkpoint blockade therapy
CN113215253B (zh) * 2020-06-05 2022-10-25 冠科生物技术(苏州)有限公司 用于评估鼠类肿瘤模型中的免疫反应的方法和组合物
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
CN112735521B (zh) * 2021-01-22 2023-09-22 安徽医科大学第一附属医院 一种指导选择适用于抗pd-1/pd-l1免疫治疗患者的膀胱癌免疫分类系统
CN113380318B (zh) * 2021-06-07 2023-04-07 天津金域医学检验实验室有限公司 人工智能辅助流式细胞术40cd免疫表型检测方法及系统
CN117275733A (zh) * 2023-11-17 2023-12-22 中日友好医院(中日友好临床医学研究所) 基于影像组学预测肿瘤免疫状态及治疗反应的方法及装置
WO2025227286A1 (zh) * 2024-04-28 2025-11-06 浙江大学医学院附属邵逸夫医院 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用
CN118098378B (zh) * 2024-04-28 2024-07-19 浙江大学医学院附属邵逸夫医院 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用
CN119530396A (zh) * 2025-01-22 2025-02-28 中国科学院杭州医学研究所 预测肿瘤免疫治疗效果的标志物及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015528698A (ja) * 2012-07-12 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081442B1 (en) 2006-10-10 2016-08-10 TrovaGene, Inc. Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
WO2009055480A2 (en) 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
AU2009257410B2 (en) * 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
US20140017227A1 (en) * 2011-01-14 2014-01-16 Suk Peng Chew Gene signatures for use with hepatocellular carcinoma
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015528698A (ja) * 2012-07-12 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. Sep;153(3), JPN6022017660, 15 June 2017 (2017-06-15), pages 812 - 826, ISSN: 0004933814 *
HEPATOLOGY, vol. 64, JPN6022017661, 2016, pages 230 - 231, ISSN: 0004933813 *

Also Published As

Publication number Publication date
EP3638695A4 (en) 2021-06-30
WO2018232142A1 (en) 2018-12-20
CN111164103A (zh) 2020-05-15
US20210277480A1 (en) 2021-09-09
EP3638695A1 (en) 2020-04-22
US11473150B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
US11473150B2 (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
CN109715829B (zh) 一种评估预后和预测恶性疾病患者对免疫治疗的反应的方法
Hu et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage
CN113694193A (zh) 检查点阻断和微卫星不稳定性
US20170275705A1 (en) Biomarkers useful for determining response to pd-1 blockade therapy
JP2015536667A (ja) 癌のための分子診断検査
Massi et al. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients
WO2014022826A2 (en) Biomarker associated with risk of melanoma reoccurrence
Yan et al. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade
WO2013172926A1 (en) Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US20120015906A1 (en) Uses of bortezomib in predicting survival in multiple myeloma patients
EP3749330A1 (en) Repeat rna as biomarkers of tumor immune response
WO2022053065A1 (zh) 用于预测或评估肺癌患者的生物标志物、检测方法及应用
KR20190087106A (ko) 위암의 항암제 치료 반응성 예측용 바이오마커 및 이의 용도
JP2018033467A (ja) プロテアソーム阻害剤に応答するバイオマーカー
WO2017114851A1 (en) Methods for predicting the survival time of patients suffering from a microsatellite unstable cancer
JP2024526977A (ja) 免疫療法後の治療反応のためのバイオマーカー
Blanco-Heredia et al. Converging and evolving immuno-genomic routes toward immune escape in breast cancer
US11685955B2 (en) Method for predicting response of patients with malignant diseases to immunotherapy
JP7128270B2 (ja) 免疫療法に対する悪性疾患の応答性を決定するための方法
WO2023081889A1 (en) Methods for treatment of cancer
WO2018122249A1 (en) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
Yang et al. Multi-omics analysis of the biological function of the VEGF family in colon adenocarcinoma
HK40031046A (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
CN120700149A (zh) 预测黑色素瘤预后和免疫治疗响应的生物标志物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221130